文献速递主动脉疾病

TGF-β中和精细调控弹性蛋白酶诱导腹主动脉瘤巨噬细胞表型并增加主动脉ARG1表达

Transforming growth factor β neutralization finely tunes macrophage phenotype in elastase-induced abdominal aortic aneurysm and is associated with an increase of arginase 1 expression in the aorta.
PubMed 文献 · J Vasc Surg · 2019-02-18

该研究在小鼠弹性蛋白酶诱导的腹主动脉瘤模型中,探讨全身阻断TGF-β对巨噬细胞表型及主动脉ARG1表达的影响。结果显示TGF-β中和显著增加ARG1基因和蛋白表达,且人腹主动脉瘤组织ARG1表达亦升高。提示ARG1可能成为腹主动脉瘤预后或治疗新靶点。

要点

  • 弹性蛋白酶联合抗TGF-β小鼠模型中,主动脉ARG1、IL-1β和IL-6基因表达显著增加。
  • 巨噬细胞清除后,抗TGF-β组IL-1β、IL-6、ARG1和Ym1/2基因表达显著下降。
  • 人腹主动脉瘤组织ARG1蛋白表达较对照升高,阳性细胞主要位于外膜。

核心结论

  • TGF-β中和可精细调控弹性蛋白酶诱导腹主动脉瘤的巨噬细胞表型,并增加主动脉壁ARG1基因和蛋白表达。

研究设计与样本

  • C57Bl/6J雄性小鼠(6-8周龄)随机分为热灭活弹性蛋白酶组、弹性蛋白酶组及弹性蛋白酶+抗TGF-β组。
  • 弹性蛋白酶+抗TGF-β组采用脂质体氯膦酸盐清除单核-巨噬细胞。
  • 获取10例人肾下腹主动脉瘤组织分析ARG1表达。

主要发现

  • 14天后,弹性蛋白酶组与弹性蛋白酶+抗TGF-β组间CCL2、NOS2和Ym1/2基因表达无显著差异。
  • 弹性蛋白酶+抗TGF-β组ARG1、IL-1β和IL-6基因表达较弹性蛋白酶组显著增加。
  • 巨噬细胞清除后,弹性蛋白酶+抗TGF-β组IL-1β、IL-6、ARG1和Ym1/2基因表达显著下降。
  • 免疫荧光证实TGF-β中和显著增强动脉瘤组织ARG1蛋白表达。
  • 流式细胞术显示弹性蛋白酶+抗TGF-β组主动脉ARG1阳性巨噬细胞增加,且比例随动脉瘤扩张而升高。

临床怎么用

  • ARG1可能作为腹主动脉瘤预后或治疗靶点,但需进一步研究阐明其在瘤发展中的作用。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Macrophages play a critical role in the initiation and progression of abdominal aortic aneurysm (AAA) and are classically distinguished into M1 "proinflammatory" and M2 "anti-inflammatory" macrophages. Topical application of elastase associated with transforming growth factor β (TGF-β) systemic neutralization reproduces the main pathologic features of human AAA, offering a new model to investigate their role. The aim of this study was to investigate whether macrophages contribute to the expression of canonical M1/M2 markers in the aorta in the AAA model induced by elastase and systemic blockade of TGF-β and whether blocking of TGF-β activity affects macrophage phenotype and the expression of the M2 marker arginase 1 (ARG1). METHODS: C57Bl/6J male mice (6-8 weeks old) were randomly assigned to three experimental groups: mice that had local application of heat-inactivated elastase or elastase and mice that had elastase application and received injection of anti-TGF-β (elastase + anti-TGF-β group). Monocyte-macrophage depletion was achieved in the elastase + anti-TGF-β group using liposome clodronate. Macrophage phenotype was characterized by quantitative polymerase chain reaction, flow cytometry, and immunohistochemistry. Human infrarenal AAA tissues (n = 10) were obtained to analyze ARG1 expression. RESULTS: Analysis of gene expression in the infrarenal aortic wall revealed that after 14 days, no significant difference for the expression of CCL2, NOS2, and Ym1/2 was observed in the elastase group compared with the elastase + anti-TGF-β group, whereas the expression of ARG1, interleukin (IL) 1β, and IL-6 was significantly increased. Macrophage depletion in the elastase + anti-TGF-β group led to a significant decrease of IL-1β, IL-6, ARG1, and Ym1/2 gene expression. Immunofluorescent staining confirmed that TGF-β neutralization significantly enhanced ARG1 protein expression in the aneurysmal tissue. Flow cytometry analysis revealed an increase of macrophages expressing ARG1 in the aorta of mice treated with elastase + anti-TGF-β compared with the elastase group, and their proportion increased with aneurysmal dilation. In humans, ARG1 protein expression was increased in aneurysmal tissues compared with controls, and positive cells were mainly found in the adventitia. CONCLUSIONS: TGF-β neutralization finely tunes macrophage phenotype in elastase-induced AAA and leads to an increase in ARG1 gene and protein expression in the aortic wall. Even if further studies are required to elucidate its role in AAA development, ARG1 could represent a new prognostic or therapeutic target in aneurysmal disease.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Raffort J, Lareyre F, Clément M, et al. Transforming growth factor β neutralization finely tunes macrophage phenotype in elastase-induced abdominal aortic aneurysm and is associated with an increase of arginase 1 expression in the aorta. J Vasc Surg. 2019. PMID: 30792060. doi:10.1016/j.jvs.2018.09.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。